NIKKEI 225
38,946.93 -122.75 (-0.31%) HANG SENG
19,220.62 -415.60 (-2.12%) CRUDE OIL
79.19 -0.61 (-0.76%) GOLD FUTURES
2,422.70 -15.80 (-0.65%) DOW
39,835.84 +29.07 (+0.07%) Bitcoin GBP
54,843.49 +984.66 (+1.83%)
Evolus, Inc. (EOLS)
| Previous close | 13.42 |
| Open | 13.38 |
| Bid | 13.15 x 100 |
| Ask | 13.21 x 100 |
| Day's range | 13.11 - 13.49 |
| 52-week range | 7.07 - 15.43 |
| Volume | |
| Avg. volume | 645,079 |
| Market cap | 823.954M |
| Beta (5Y monthly) | 1.48 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting
NEWPORT BEACH, Calif., May 20, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal nasolabial fold (NLF) study of dermal filler products Evolysse™ Lift and Smooth. Data were presented at the 2024 SCALE Meeting on May 17, 2024, in Nashville.
- Business Wire
Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO Summit
NEWPORT BEACH, Calif., May 15, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced its participation in the Women’s Wear Daily (WWD) Beauty CEO Summit. This summit brings together the leading retailers, marketers, and creative minds across all categories to help prepare for the next phase of global beauty while driving growth and innovation today. At the global consumer beauty event, President and Chi
- Business Wire
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWPORT BEACH, Calif., May 10, 2024--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,990 shares of Evolus and an aggregate of 42,759 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’s board of dir
